TCA

(redirected from tricyclic antidepressant)
Also found in: Dictionary, Thesaurus, Medical, Financial, Acronyms, Wikipedia.

TCA

(organic chemistry)
References in periodicals archive ?
Electrocardiographic criteria for tricyclic antidepressant cardiotoxicity.
Tricyclic antidepressant poisoning: an evidence-based consensus guideline for out-of-hospital management.
Major Finding: Compared directly with tricyclic antidepressants, SSRIs were associated with significantly higher rates of all-cause death (adjusted hazard ratio, 1.
Tricyclic antidepressants act primarily on sodium (fast) channels but also on delayed rectifier potassium (IKr) channels.
A statistically significant association was found between respondents taking or not taking tricyclic antidepressant therapy and cataplexy symptom ratings ([chi square] = 10.
A/ TRICYCLIC ANTIDEPRESSANTS, duloxetine, pregabalin, oxycodone, and tramadol are all effective for the symptomatic treatment of painful diabetic neuropathy (strength of recommendation [SOR]: A, systematic reviews of randomized controlled trials [RCTs] and single RCTs).
Common prescription medications that cause constipation in this patient population include opioid, anticholingeric or tricyclic antidepressant agents.
In a cohort study of 14,784 adults without known CVD in Scotland, the use of tricyclic antidepressants (TCAs) for any amount of time and for any reason was associated with a 35% higher risk of being diagnosed with CVD within 8 years, even after accounting for potential confounders, including symptoms of anxiety and depression, which are also linked to CVD.
17, 2008 issue of Neurology, scientists gave 52 people diagnosed with Parkinson's disease and depression either nortriptyline, a tricyclic antidepressant (TCA); paroxetine CR, a selective serotonin reuptake inhibitor (SSRI); or placebo.
We report a case of refractory hypotension that occurred after epidural injection of local anaesthetic, in a patient who was receiving tricyclic antidepressant therapy and was under general anaesthesia.
No Food and Drug Administration-approved tricyclic antidepressant in the Tufts review showed a low potential risk of carcinogenicity (defined as no positive preclinical or clinical studies or only negative studies).